President and Chief Scientific Officer
Zhittya Genesis Medicine, Inc
Las Vegas, Nevada (USA)
Dr. Jacobs received his BS degree from Davidson College, Davidson, North Carolina and a Ph.D. in molecular biology from Washington University, St. Louis, Missouri. He has been involved in the healthcare industry for over 25 years and has extensive expertise in supervising drug manufacturing operations and the design and implementation of preclinical animal trials and US FDA-authorized clinical trials. He started a new department of Biological Chemistry at the pharmaceutical company, Merck, and for 15 years worked as the Chief Science Officer of CardioVascular BioTherapeutics, Inc. where he oversaw FDA-authorized clinical trials in which the angiogenesis drug candidate, human FGF-1, was tested in a number of medical indications, including coronary artery disease, diabetic foot ulcers and peripheral artery disease. He has been continuing these drug development activities with FGF-1 at Zhittya Genesis Medicine, concentrating on the potential role of “therapeutic angiogenesis” to treat neurodegenerative diseases, including Parkinson’s disease.